QNTM
NASDAQ · Pharmaceuticals
Quantum Biopharma-B Sub Vot
$4.71
-0.02 (-0.42%)
Financial Highlights (FY 2026)
Revenue
10.42M
Net Income
-380,383,734
Gross Margin
-641.6%
Profit Margin
-19,353.5%
Rev Growth
—
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | -641.6% | 62.6% | 62.6% | 62.6% |
| Operating Margin | -13,644.5% | 31.3% | 29.9% | 25.4% |
| Profit Margin | -19,353.5% | 24.2% | 17.2% | 20.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 10.42M | 7.61M | 6.92M | 6.74M |
| Gross Profit | -66,854,997 | 4.77M | 4.34M | 4.23M |
| Operating Income | -1,421,807,111 | 2.38M | 2.07M | 1.71M |
| Net Income | -380,383,734 | 1.84M | 1.19M | 1.39M |
| Gross Margin | -641.6% | 62.6% | 62.6% | 62.6% |
| Operating Margin | -13,644.5% | 31.3% | 29.9% | 25.4% |
| Profit Margin | -19,353.5% | 24.2% | 17.2% | 20.6% |
| Rev Growth | — | +16.6% | +5.5% | +24.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 108.8K | 6.68M | 6.34M | 7.12M |
| Total Equity | 6.44M | 10.50M | 9.75M | 8.98M |
| D/E Ratio | 0.02 | 0.64 | 0.65 | 0.79 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -320,137,952 | 2.64M | 2.30M | 2.54M |
| Free Cash Flow | — | 1.03M | 1.07M | 803.7K |